Tirzepatide and semaglutide often show up in the same search, because both are incretin-class research peptides. The difference is not which one is "stronger", it is which receptor profile and which use protocol a given study is asking about.

Receptor profile: one target versus two

Semaglutide is a GLP-1 receptor mono-agonist. Tirzepatide is described as a synthetic dual-axis agonist that acts on both the GIP and GLP-1 receptors at once. These are different molecules with different structures, not two doses of the same substance.

Research context in the literature

Semaglutide has the published STEP program, which studied weight management under controlled protocols. Tirzepatide has separate SURPASS (glycemic control) and SURMOUNT (weight management) programs, covered in more detail in the SURPASS-2 and SURMOUNT-1 design breakdown. A direct numeric comparison across different programs is not valid: different populations, different durations, different control arms.

What this means when choosing a catalog sample

There is no clinical "winner" for a research purpose, only the question of which receptor mechanism fits a specific lab's protocol. Both catalog molecules carry the same documentation standard: a public certificate of analysis (COA) for every batch, with the LOT number on the label matching the number in the document.

ParameterTirzepatideSemaglutide
Receptor targetGIP + GLP-1 (dual)GLP-1 (mono)
Research programSURPASS / SURMOUNTSTEP
Catalogtirzepatide listingsemaglutide listing

Wiki references

Full molecule references: tirzepatide and semaglutide.

RUO, not a medical product

Both samples in the Longeva catalog carry research-use-only status. That means laboratory use, not a dosing recommendation or a claim of effect for humans. A publication in a clinical journal describes the molecule's effect under a controlled protocol, not the properties of a specific vial, that needs a COA for its own exact batch.

This material is for reference only and is not medical advice, diagnosis, or a prescription.